Recent studies have summarized the factors contributing to the improved immunotherapeutic outcome of IRE in combination with PD‐1 in mouse tumor models, with three potential immunological mechanisms that may be responsible for enhancing tumor immune responses and collaborating to achieve anti‐tumor effects. The gene discussed is PDCD1; the disease is neoplasm.